Epidemiology of acquired immunodeficiency syndrome: Advancing to an endemic era

American Journal of Medicine

Volumn 102, Issue 4 A, 1997, Pages 2-8

  Graham, Neil M H ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CONFERENCE PAPER; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALIVA ANALYSIS; SCREENING TEST; SERODIAGNOSIS; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 0030985110     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)00031-4     Document Type: Conference Paper

References (34)

1. Centers for Disease Control and Prevention. First 500,000 AIDS cases - United States, 1995. MMWR. 1995;44:849-853.
2. National Center for Health Statistics. Annual summary of births, marriages, divorces, and deaths: United States, 1993. Monthly vital health statistics; vol. 42, no 13. Hyattsville, MD: Public Health Service, 1994: 18-20.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report Mid-Year Edition. 1995;7:1-34.
4. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science. 1995;270:1372-1375.
5. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science. 1991;253:37-42.
6. Centers for Disease Control and Prevention. Update: AIDS among women - United States, 1994. MMWR. 1995;44:81-84.
7. Wortley PM, Chu SY, Diaz T, et al. HIV testing patterns: where, why, and when were persons with AIDS tested for HIV? AIDS. 1995;9:487-492.
8. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011-1018.
9. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-362.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
11. Wei X, Shosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
12. Enger C, Graham NMH, Peng Y, et al. Survival from early, intermediate and late stages of HIV infection. JAMA. 1996;275:1329-1334.
13. Hammer SM, Katzenstein DA, Hughes MD, Hirsch MS, Merigan TC, for the ACTG 175 Virology Substudy Team. Virologic markers and outcome in ACTG 175. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 2, 1996; Washington, DC. Abstract S24.
14. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995:333:1662-1669.
15. 3. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 2, 1996; Washington, DC. Abstract 199.
16. Gazzard B. Delta Study. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 2, 1996. Washington, DC. Abstract LB5A.
17. Saravolatz L. CPCRA Protocol 007. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 2, 1996. Washington, DC. Abstract LB4.
18. Graham N, Hoover DR, Park LP, et al. Survival in zidovudine-experienced patients: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med. 1996;124:1031-1038.
19. Larder BA, Kemp SD, Harrigan P. Potential mechanisms for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
20. Gwinn M, Pappaionou M, George JR, et al. Prevalence of HIV infection in childbearing women in the United States. JAMA. 1991;265:1704-1708.
21. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, Year-end Edition. 1994;6:1-13.
22. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-fetal transmission of HIV type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
23. Barbacci M, Repke JT, Chaisson RE. Routine prenatal screening for HIV infection. Lancet. 1991;337:709-711.
24. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of HIV. MMWR. 1994;43:1-21.
25. Centers for Disease Control and Prevention. Minimal Data Set for Risk Reduction Reporting Period January 1, 1994-December 31, 1994. National Summary.
26. Mayes S, Elsesser V, Schaefer JH, Handford HA, Michael-Good L. Sexual practices and AIDS knowledge among women partners of HIV-infected hemophiliacs. Public Health Rep 1992;107:504-513.
27. Hu DJ, Byers R, Fleming PL, War JW. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prev Med. 1995;11:114-119.
28. Blendon RJ, Aiken LH, Freeman HE, et al. Access to medical care for black and white Americans: a matter of continuing concern. JAMA. 1989;261:278-281.
29. Easterbrook PJ, Deruly JC, Crengh-Kirk T, et al. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. JAMA. 1991;2667:2713-2718.
30. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care. 1992;30:17-29.
31. Lagakos S, Fischl MA, Stein DS, Lim I, Volberding P. Effects of zidovudine therapy in minority and other subpopulations in early HIV infection. JAMA. 1991;266:2709-2712.
32. Zucconi SL, Jacobson LP, Schrager LK, et al. Impact of immunosuppression on health care use by men in the multicenter AIDS cohort study (MACS). J Acquir Immune Defic Syndr. 1994;7:607-616.
33. Solomon L. Factors associated with initiation of ZDV in IDUs. J Drug Issues. 1995;25:225-233.
34. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Presented at the 3rd Conference on Retroviruses and Opportunistic Infections; January 28-February 2, 1996; Washington, DC. Abstract LB7.